Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urogenital Neoplasms 1Prostatic Neoplasms 1Prostatic Diseases 1Neoplasms by Site 1Neoplasms 1Male Urogenital Diseases 1Genital Neoplasms, Male 1Genital Diseases, Male 1Carcinoma 1

Interventions

Cisplatin 21pembrolizumab 16Gemcitabine 16Paclitaxel 15Radiotherapy 14Carboplatin 14Radiotherapy, Intensity-Modulated 13Cyclophosphamide 9Cetuximab 9Magnetic Resonance Spectroscopy 8Radiation 7padeliporfin 6Specimen Handling 6Oxaliplatin 6Fluorouracil 6Drug Therapy 6Docetaxel 6Capecitabine 6Bevacizumab 6anlotinib 5Nivolumab 5Irinotecan 5Erlotinib Hydrochloride 5Celecoxib 5poly ICLC 4fludarabine 4Standard of Care 4Sorafenib 4Leucovorin 4Ipilimumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma × palladium-bacteriopheophorbide × Clear all
NCT04225299 2020-11-13

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

Steba Biotech S.A.

Phase 3 Withdrawn
Genitourinary

Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡